Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 126.40
+2.70 (2.18%)
At close: Mar 27, 2026
Akeso Revenue
In the year 2025, Akeso had annual revenue of 3.06B CNY with 43.90% growth. Akeso had revenue of 1.64B in the half year ending December 31, 2025, with 93.64% growth.
Revenue
3.06B CNY
Revenue Growth
+43.90%
P/S Ratio
34.23
Revenue / Employee
866.05K CNY
Employees
3,529
Market Cap
116.43B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.06B | 932.33M | 43.90% |
| Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
| Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
| Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
| Dec 31, 2021 | 225.63M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 41.59B |
| Sino Biopharmaceutical | 35.43B |
| WuXi Biologics | 24.25B |
| Innovent Biologics | 14.51B |
| 3SBio | 9.94B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.62B |
| Shanghai Junshi Biosciences | 2.78B |
Akeso News
- 2 days ago - Akeso Reports Full-Year 2025 Financial Results - PRNewsWire
- 4 days ago - Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab - PRNewsWire
- 13 days ago - Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance - PRNewsWire
- 24 days ago - Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results - PRNewsWire
- 6 weeks ago - Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications - PRNewsWire
- 7 weeks ago - Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer - PRNewsWire
- 2 months ago - Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis - PRNewsWire
- 4 months ago - All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs - PRNewsWire